Gastroretentive drug delivery systems for the treatment of Helicobacter pylori

World Journal of Gastroenterology

Volumn 20, Issue 28, 2014, Pages 9321-9329

  Zhao, Shan ^a,b   Lv, Yan ^a,b   Zhang, Jian Bin ^a,b   Wang, Bing ^a,b   Lv, Guo Jun ^a   Ma, Xiao Jun ^a  

^a DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Bioadhesive systems; Expandable Systems; Floating systems; Gastroretentive systems; Helicobacter pylori

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; DRUG CARRIER; DRUG DOSAGE FORM; PROTON PUMP INHIBITOR;

ANTIBIOTIC THERAPY; ARTICLE; BIOADHESIVE DRUG DELIVERY SYSTEM; DIGESTIVE TRACT PARAMETERS; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG RETENTION; EXPANDABLE DRUG DELIVERY SYSTEM; FLOATING DRUG DELIVERY SYSTEM; GASTRORETENTIVE DRUG DELIVERY SYSTEM; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MEAN RESIDENCE TIME; NONHUMAN; PATHOPHYSIOLOGY; ANIMAL; CHEMISTRY; DRUG COMBINATION; DRUG EFFECTS; HELICOBACTER INFECTIONS; MEDICINAL CHEMISTRY; MICROBIOLOGY; ORAL DRUG ADMINISTRATION; PHARMACEUTICS; PROCEDURES; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; CHEMISTRY, PHARMACEUTICAL; DOSAGE FORMS; DRUG CARRIERS; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PROTON PUMP INHIBITORS; TECHNOLOGY, PHARMACEUTICAL; TREATMENT OUTCOME;

EID: 84908869529     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i28.9321     Document Type: Article

References (102)

1. Goh KL, Chan WK, Shiota S, Yamaoka Y. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter 2011; 16 Suppl 1: 1-9 [PMID: 21896079 DOI: 10.1111/j.1523-5378.2011.00874.x]
2. Gisbert JP. [Helicobacter pylori-related diseases]. Gastroenterol Hepatol 2012; 35 Suppl 1: 12-25 [PMID: 23018004]
3. Umamaheshwari RB, Jain S, Jain NK. A new approach in gastroretentive drug delivery system using cholestyramine. Drug Deliv 2003; 10: 151-160 [PMID: 12944135 DOI: 10.1080/713840399]
4. Shah S, Qaqish R, Patel V, Amiji M. Evaluation of the factors influencing stomach-specific delivery of antibacterial agents for Helicobacter pylori infection. J Pharm Pharmacol 1999; 51: 667-672 [PMID: 10454042 DOI: 10.1211/0022357991772952]
5. Nagahara N, Akiyama Y, Nakao M, Tada M, Kitano M, Ogawa Y. Mucoadhesive microspheres containing amoxicillin for clearance of Helicobacter pylori. Antimicrob Agents Chemother 1998; 42: 2492-2494 [PMID: 9756746]
6. Pawar VK, Kansal S, Garg G, Awasthi R, Singodia D, Kulkarni GT. Gastroretentive dosage forms: a review with special emphasis on floating drug delivery systems. Drug Deliv 2011; 18: 97-110 [PMID: 20958237 DOI: 10.3109/107175 44.2010.520354]
7. Hwang SJ, Park H, Park K. Gastric retentive drug-delivery systems. Crit Rev Ther Drug Carrier Syst 1998; 15: 243-284 [PMID: 9699081]
8. Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori. Clin Microbiol Rev 1997; 10: 720-741 [PMID: 9336670]
9. Marshall B. Helicobacter pylori: 20 years on. Clin Med 2002; 2: 147-152 [PMID: 11991099 DOI: 10.7861/clinmedicine.2-2-147]
10. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991; 325: 1127-1131 [PMID: 1891020 DOI: 10.1056/NEJM199110173251603]
11. Yamada T, Ahnen D, Alpers DH, Greenberg HB, Gray L, Joscelyn KB, Kauffman G, Podolsky DK, Ray WA, Schaberg D, Silverstein FE, Sivak MV, Williams ALB, Yolken R. Helicobacter-Pylori in Peptic-Ulcer Disease. Jama-J Am Med Assoc 1994; 272: 65-69 [DOI: 10.1001/jama.1994.03520010077036]
12. Singh K, Ghoshal UC. Causal role of Helicobacter pylori infection in gastric cancer: an Asian enigma. World J Gastroenterol 2006; 12: 1346-1351 [PMID: 16552799]
13. Goodwin CS, Armstrong JA. Microbiological aspects of Helicobacter pylori (Campylobacter pylori). Eur J Clin Microbiol Infect Dis 1990; 9: 1-13 [PMID: 2406141 DOI: 10.1007/BF01969526]
14. Geis G, Suerbaum S, Forsthoff B, Leying H, Opferkuch W. Ultrastructure and biochemical studies of the flagellar sheath of Helicobacter pylori. J Med Microbiol 1993; 38: 371-377 [PMID: 8487294 DOI: 10.1099/00222615-38-5-371]
15. Semino-Mora C, Doi SQ, Marty A, Simko V, Carlstedt I, Dubois A. Intracellular and interstitial expression of Helicobacter pylori virulence genes in gastric precancerous intestinal metaplasia and adenocarcinoma. J Infect Dis 2003; 187: 1165-1177 [PMID: 12695995 DOI: 10.1086/368133]
16. Krajewska B. Ureases I. Functional, catalytic and kinetic properties: A review. J Mol Catal B-Enzym 2009; 59: 9-21 [DOI: 10.1016/j.molcatb.2009.01.003]
17. Atherton JC. The pathogenesis of Helicobacter pyloriinduced gastro-duodenal diseases. Annu Rev Pathol 2006; 1: 63-96 [PMID: 18039108 DOI: 10.1146/annurev. pathol.1.110304.100125]
18. Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006; 19: 449-490 [PMID: 16847081 DOI: 10.1128/CMR.00054-05]
19. Blaser MJ, Atherton JC. Helicobacter pylori persistence: biology and disease. J Clin Invest 2004; 113: 321-333 [PMID: 14755326 DOI: 10.1172/JCI20925]
20. Cover TL, Blaser MJ. Purification and characterization of the vacuolating toxin from Helicobacter pylori. J Biol Chem 1992; 267: 10570-10575 [PMID: 1587837]
21. Guillemin K, Salama NR, Tompkins LS, Falkow S. Cag pathogenicity island-specific responses of gastric epithelial cells to Helicobacter pylori infection. Proc Natl Acad Sci USA 2002; 99: 15136-15141 [PMID: 12411577 DOI: 10.1073/pnas.182558799]
22. Genta RM, Graham DY. Helicobacter pylori: the new bug on the (paraffin) block. Virchows Arch 1994; 425: 339-347 [PMID: 7820298 DOI: 10.1007/BF00189571]
23. Cid TP, Fernández MC, Benito Martínez S, Jones NL. Pathogenesis of Helicobacter pylori infection. Helicobacter 2013; 18 Suppl 1: 12-17 [PMID: 24011239 DOI: 10.1111/hel.12076]
24. Oertli M, Noben M, Engler DB, Semper RP, Reuter S, Maxeiner J, Gerhard M, Taube C, Müller A. Helicobacter pylori γ-glutamyl transpeptidase and vacuolating cytotoxin promote gastric persistence and immune tolerance. Proc Natl Acad Sci USA 2013; 110: 3047-3052 [PMID: 23382221 DOI: 10.1073/pnas.1211248110]
25. Goodgame RW, Malaty HM, el-Zimaity HM, Graham DY. Decrease in gastric permeability to sucrose following cure of Helicobacter pylori infection. Helicobacter 1997; 2: 44-47 [PMID: 9432322 DOI: 10.1111/j.1523-5378.1997.tb00057.x]
26. Borch K, Sjöstedt C, Hannestad U, Söderholm JD, Franzén L, Mårdh S. Asymptomatic Helicobacter pylori gastritis is associated with increased sucrose permeability. Dig Dis Sci 1998; 43: 749-753 [PMID: 9558030 DOI: 10.1023/A:1018809913230]
27. Noach LA, Rolf TM, Tytgat GN. Electron microscopic study of association between Helicobacter pylori and gastric and duodenal mucosa. J Clin Pathol 1994; 47: 699-704 [PMID: 7962619 DOI: 10.1136/jcp.47.8.699]
28. McColl KE. Helicobacter pylori and acid secretion: where are we now? Eur J Gastroenterol Hepatol 1997; 9: 333-335 [PMID: 9160194 DOI: 10.1097/00042737-199704000-00004]
29. Go MF, Kapur V, Graham DY, Musser JM. Population genetic analysis of Helicobacter pylori by multilocus enzyme electrophoresis: extensive allelic diversity and recombinational population structure. J Bacteriol 1996; 178: 3934-3938 [PMID: 8682800]
30. O'Connor A, Gisbert JP, McNamara D, O'Morain C. Treatment of Helicobacter pylori Infection 2011. Helicobacter 2011; 16 (Suppl 1): 6
31. Cavallaro LG, Egan B, O'Morain C, Di Mario F. Treatment of Helicobacter pylori infection. Helicobacter 2006; 11 Suppl 1: 36-39 [PMID: 16925610 DOI: 10.1111/j.1478-405X.2006.00428.x]
32. Gumurdulu Y, Serin E, Ozer B, Kayaselcuk F, Ozsahin K, Cosar AM, Gursoy M, Gur G, Yilmaz U, Boyacioglu S. Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey. World J Gastroenterol 2004; 10: 668-671 [PMID: 14991935]
33. Ogata SK, Godoy AP, da Silva Patricio FR, Kawakami E. High Helicobacter pylori resistance to metronidazole and clarithromycin in Brazilian children and adolescents. J Pediatr Gastroenterol Nutr 2013; 56: 645-648 [PMID: 23403439]
34. Gomollón F, Santolaria S, Sicilia B, Ferrero M, Revillo MJ, Ducóns J, Villar M, Celaya MC, Montoro M. [Helicobacter pylori resistance to metronidazole and clarythromicin: descriptive analysis 1997-2000]. Med Clin (Barc) 2004; 123: 481-485 [PMID: 15511367 DOI: 10.1016/S0025-7753(04)74566-2]
35. Mégraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53: 1374-1384 [PMID: 15306603 DOI: 10.1136/gut.2003.022111]
36. Seddik H, Ahid S, El Adioui T, El Hamdi FZ, Hassar M, Abouqal R, Cherrah Y, Benkirane A. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a prospective randomized study. Eur J Clin Pharmacol 2013; 69: 1709-1715 [PMID: 23695545 DOI: 10.1007/s00228-013-1524-6]
37. Lim JH, Lee DH, Choi C, Lee ST, Kim N, Jeong SH, Kim JW, Hwang JH, Park YS, Lee SH, Shin CM, Jo HJ, Jang ES, Song Is, Jung HC. Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study. Helicobacter 2013; 18: 180-186 [PMID: 23305083]
38. Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 2008; 148: 923-931 [PMID: 18490667 DOI: 10.7326/0003-4819-149-6-200809160-00022]
39. Tsay FW, Tseng HH, Hsu PI, Wang KM, Lee CC, Chang SN, Wang HM, Yu HC, Chen WC, Peng NJ, Lai KH, Wu DC. Sequential therapy achieves a higher eradication rate than standard triple therapy in Taiwan. J Gastroenterol Hepatol 2012; 27: 498-503 [PMID: 21871025 DOI: 10.1111/j.1440-1746.2011.06885.x]
40. Molina-Infante J, Romano M, Fernandez-Bermejo M, Federico A, Gravina AG, Pozzati L, Garcia-Abadia E, Vinagre-Rodriguez G, Martinez-Alcala C, Hernandez-Alonso M, Miranda A, Iovene MR, Pazos-Pacheco C, Gisbert JP. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology 2013; 145: 121-128.e1 [PMID: 23562754 DOI: 10.1053/j.gastro.2013.03.050]
41. Molina-Infante J, Pazos-Pacheco C, Vinagre-Rodriguez G, Perez-Gallardo B, Dueñas-Sadornil C, Hernandez-Alonso M, Gonzalez-Garcia G, Mateos-Rodriguez JM, Fernandez-Bermejo M, Gisbert JP. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains. Helicobacter 2012; 17: 269-276 [PMID: 22759326 DOI: 10.1111/j.1523-5378.2012.00947.x]
42. Hsu PI, Wu DC, Wu JY, Graham DY. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter 2011; 16: 139-145 [PMID: 21435092 DOI: 10.1111/j.1523-5378.2011.00828.x]
43. Kuo CH, Kuo FC, Hu HM, Liu CJ, Wang SS, Chen YH, Hsieh MC, Hou MF, Wu DC. The Optimal First-Line Therapy of Helicobacter pylori Infection in Year 2012. Gastroenterol Res Pract 2012; 2012: 168361 [PMID: 22792095 DOI: 10.1155/2012/168361]
44. Sardarian H, Fakheri H, Hosseini V, Taghvaei T, Maleki I, Mokhtare M. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial. Helicobacter 2013; 18: 129-134 [PMID: 23121338 DOI: 10.1111/hel.12017]
45. Bardonnet PL, Faivre V, Pugh WJ, Piffaretti JC, Falson F. Gastroretentive dosage forms: overview and special case of Helicobacter pylori. J Control Release 2006; 111: 1-18 [PMID: 16403588]
46. Strid H, Simrén M, Stotzer PO, Abrahamsson H, Björnsson ES. Delay in gastric emptying in patients with chronic renal failure. Scand J Gastroenterol 2004; 39: 516-520 [PMID: 15223673]
47. Horowitz M, Wishart JM, Jones KL, Hebbard GS. Gastric emptying in diabetes: an overview. Diabet Med 1996; 13: S16-S22 [PMID: 8894465]
48. Leontiadis GI, Minopoulos GI, Maltezos E, Kotsiou S, Manolas KI, Simopoulos K, Hatseras D. Effects of Helicobacter pylori infection on gastric emptying rate in patients with non-ulcer dyspepsia. World J Gastroenterol 2004; 10: 1750-1754 [PMID: 15188499]
49. McHugh PR, Moran TH. Calories and gastric emptying: a regulatory capacity with implications for feeding. Am J Physiol 1979; 236: R254-R260 [PMID: 109014]
50. Kwiatek MA, Menne D, Steingoetter A, Goetze O, Forras-Kaufman Z, Kaufman E, Fruehauf H, Boesiger P, Fried M, Schwizer W, Fox MR. Effect of meal volume and calorie load on postprandial gastric function and emptying: studies under physiological conditions by combined fiber-optic pressure measurement and MRI. Am J Physiol Gastrointest Liver Physiol 2009; 297: G894-G901 [PMID: 19779010 DOI: 10.1152/ajpgi.00117.2009]
51. Hunt JN, Stubbs DF. The volume and energy content of meals as determinants of gastric emptying. J Physiol 1975; 245: 209-225 [PMID: 1127608]
52. Kaniwa N, Aoyagi N, Ogata H, Ejima A. Gastric emptying rates of drug preparations. I. Effects of size of dosage forms, food and species on gastric emptying rates. J Pharmacobiodyn 1988; 11: 563-570 [PMID: 3236214 DOI: 10.1248/bpb1978.11.563]
53. Timmermans J, Moës AJ. The cutoff size for gastric emptying of dosage forms. J Pharm Sci 1993; 82: 854 [PMID: 8377128 DOI: 10.1002/jps.2600820821]
54. Khosla R, Davis SS. The Effect of Tablet Size on the Gastric-Emptying of Nondisintegrating Tablets. Inter J Pharm 1990; 62: R9-R11 [DOI: 10.1016/0378-5173(90)90243-W]
55. Coupe AJ, Davis SS, Evans DF, Wilding IR. Correlation of the gastric emptying of nondisintegrating tablets with gastrointestinal motility. Pharm Res 1991; 8: 1281-1285 [PMID: 1796047]
56. Sigurdsson HH, Kirch J, Lehr CM. Mucus as a barrier to lipophilic drugs. Int J Pharm 2013; 453: 56-64 [PMID: 23727593 DOI: 10.1016/j.ijpharm.2013.05.040]
57. Larhed AW, Artursson P, Gråsjö J, Björk E. Diffusion of drugs in native and purified gastrointestinal mucus. J Pharm Sci 1997; 86: 660-665 [PMID: 9188047 DOI: 10.1021/js960503w]
58. Getyala A, Gangadharappa HV, Prasad MS, Reddy MP, Kumar TM. Formulation and evaluation of non-effervescent floating tablets of losartan potassium. Curr Drug Deliv 2013; 10: 620-629 [PMID: 23286884]
59. Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release 2000; 63: 235-259 [PMID: 10601721 DOI: 10.1016/S0168-3659(99)00204-7]
60. Wettrell K, Pandolfi M. Effect of oral administration of various beta-blocking agents on the intraocular pressure in healthy volunteers. Exp Eye Res 1975; 21: 451-456 [PMID: 1282 DOI: 10.1615/CritRevTherDrugCarrierSyst.v19.i6.20]
61. Wei Z, Yu Z, Bi D. Design and evaluation of a two-layer floating tablet for gastric retention using cisapride as a model drug. Drug Dev Ind Pharm 2001; 27: 469-474 [PMID: 11448055 DOI: 10.1081/DDC-100104323]
62. Chen YC, Lee LW, Ho HO, Sha C, Sheu MT. Evaluation of water uptake and mechanical properties of blended polymer films for preparing gas-generated multiple-unit floating drug delivery systems. J Pharm Sci 2012; 101: 3811-3822 [PMID: 22833214 DOI: 10.1002/jps.23279]
63. Prinderre P, Sauzet C, Fuxen C. Advances in gastro retentive drug-delivery systems. Expert Opin Drug Deliv 2011; 8: 1189-1203 [PMID: 21671821 DOI: 10.1517/17425247.2011.592 828]
64. Gröning R, Cloer C, Georgarakis M, Müller RS. Compressed collagen sponges as gastroretentive dosage forms: in vitro and in vivo studies. Eur J Pharm Sci 2007; 30: 1-6 [PMID: 17101267 DOI: 10.1016/j.ejps.2006.08.003]
65. Ishak RA, Awad GA, Mortada ND, Nour SA. Preparation, in vitro and in vivo evaluation of stomach-specific metronidazole-loaded alginate beads as local anti-Helicobacter pylori therapy. J Control Release 2007; 119: 207-214 [PMID: 17412443 DOI: 10.1016/j.jconrel.2007.02.012]
66. Sriamornsak P, Thirawong N, Puttipipatkhachorn S. Emulsion gel beads of calcium pectinate capable of floating on the gastric fluid: effect of some additives, hardening agent or coating on release behavior of metronidazole. Eur J Pharm Sci 2005; 24: 363-373 [PMID: 15734303 DOI: 10.1016/j.ejps.2004.12.004]
67. Yang L, Eshraghi J, Fassihi R. A new intragastric delivery system for the treatment of Helicobacter pylori associated gastric ulcer: in vitro evaluation. J Control Release 1999; 57: 215-222 [PMID: 9895409 DOI: 10.1016/S0168-3659(98)00066-2]
68. Rajinikanth PS, Balasubramaniam J, Mishra B. Development and evaluation of a novel floating in situ gelling system of amoxicillin for eradication of Helicobacter pylori. Int J Pharm 2007; 335: 114-122 [PMID: 17141986 DOI: 10.1016/j.ijpharm.2006.11.008]
69. Vasir JK, Tambwekar K, Garg S. Bioadhesive microspheres as a controlled drug delivery system. Int J Pharm 2003; 255: 13-32 [PMID: 12672598 DOI: 10.1016/S0378-5173(03)00087-5]
70. Talukder R, Fassihi R. Gastroretentive delivery systems: a mini review. Drug Dev Ind Pharm 2004; 30: 1019-1028 [PMID: 15595568 DOI: 10.1081/DDC-200040239]
71. Ponchel G, Irache J. Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv Drug Deliv Rev 1998; 34: 191-219 [PMID: 10837678 DOI: 10.1016/S0169-409X(98)00040-4]
72. Huang Y, Leobandung W, Foss A, Peppas NA. Molecular aspects of muco- and bioadhesion: tethered structures and site-specific surfaces. J Control Release 2000; 65: 63-71 [PMID: 10699271 DOI: 10.1016/S0168-3659(99)00233-3]
73. Park K, Robinson JR. Bioadhesive Polymers as Platforms for Oral-Controlled Drug Delivery - Method to Study Bioadhesion. Inter J Pharm 1984; 19: 107-127 [DOI: 10.1016/0378-5173 (84)90154-6]
74. Rastogi R, Sultana Y, Aqil M, Ali A, Kumar S, Chuttani K, Mishra AK. Alginate microspheres of isoniazid for oral sustained drug delivery. Int J Pharm 2007; 334: 71-77 [PMID: 17113732 DOI: 10.1016/j.ijpharm.2006.10.024]
75. Leucuta SE, Ponchel G, Duchêne D. Oxprenolol release from bioadhesive gelatin/poly(acrylic acid) microspheres. J Microencapsul 1997; 14: 511-522 [PMID: 9229350 DOI: 10.3109/0265 2049709033835]
76. Jimenezcastellanos MR, Zia H, Rhodes CT. Mucoadhesive Drug Delivery Systems. Drug Dev Ind Pharm 1993; 19: 143-194 [DOI: 10.3109/03639049309038765]
77. Wang DA, Varghese S, Sharma B, Strehin I, Fermanian S, Gorham J, Fairbrother DH, Cascio B, Elisseeff JH. Multifunctional chondroitin sulphate for cartilage tissue-biomaterial integration. Nat Mater 2007; 6: 385-392 [PMID: 17435762 DOI: 10.1038/nmat1890]
78. Raval JA, Patel MM. Formulation and Characterization of Gastroretentive Discs Containing Famotidine. Braz Arch BiolTechn 2011; 54: 293-300 [DOI: 10.1590/S1516-89132011000200010]
79. Hejazi R, Amiji M. Chitosan-based gastrointestinal delivery systems. J Control Release 2003; 89: 151-165 [PMID: 12711440 DOI: 10.1016/S0168-3659(03)00126-3]
80. Zou W, Cao G, Xi Y, Zhang N. New approach for local delivery of rapamycin by bioadhesive PLGA-carbopol nanoparticles. Drug Deliv 2009; 16: 15-23 [PMID: 19555304 DOI: 10.1080/10717540802481307]
81. Liu Z, Lu W, Qian L, Zhang X, Zeng P, Pan J. In vitro and in vivo studies on mucoadhesive microspheres of amoxicillin. J Control Release 2005; 102: 135-144 [PMID: 15653140 DOI: 10.1016/j.jconrel.2004.06.022]
82. Patel JK, Chavda JR. Formulation and evaluation of stomach-specific amoxicillin-loaded carbopol-934P mucoadhesive microspheres for anti-Helicobacter pylori therapy. J Microencapsul 2009; 26: 365-376 [PMID: 18720199 DOI: 10.1080/02652 040802373012]
83. Zheng JH, Liu CW, Bao DC, Zhao YJ, Ma XJ. Preparation and evaluation of floating-bioadhesive microparticles containing clarithromycin for the eradication of Helicobacter pylori. J Appl Polym Sci 2006; 102: 2226-2232 [DOI: 10.1002/App.24319]
84. Rajinikanth PS, Karunagaran LN, Balasubramaniam J, Mishra B. Formulation and evaluation of clarithromycin microspheres for eradication of Helicobacter pylori. Chem Pharm Bull (Tokyo) 2008; 56: 1658-1664 [PMID: 19043235 DOI: 10.1248/cpb.56.1658]
85. Klausner EA, Lavy E, Friedman M, Hoffman A. Expandable gastroretentive dosage forms. J Control Release 2003; 90: 143-162 [PMID: 12810298 DOI: 10.1016/S0168-3659(03)00203-7]
86. Nayak AK, Malakar J, Sen KK. Gastroretentive drug delivery technologies: current approaches and future potential. J Pharm Educ Res 2010; 1: 12
87. Gröning R, Cloer C, Müller RS. Development and in vitro evaluation of expandable gastroretentive dosage forms based on compressed collagen sponges. Pharmazie 2006; 61: 608-612 [PMID: 16889068]
88. Matharu AS, Motto MG, Patel MR, Simonelli AP, Dave RH. Evaluation of hydroxypropyl methylcellulose matrix systems as swellable gastro-retentive drug delivery systems (GRDDS). J Pharm Sci 2011; 100: 150-163 [PMID: 20572054 DOI: 10.1002/jps.22252]
89. Mastropietro DJ, Omidian H, Park K. Drug delivery applications for superporous hydrogels. Expert Opin Drug Deliv 2012; 9: 71-89 [PMID: 22145909 DOI: 10.1517/17425247.2012. 641950]
90. Chen J, Blevins WE, Park H, Park K. Gastric retention properties of superporous hydrogel composites. J Control Release 2000; 64: 39-51 [PMID: 10640644 DOI: 10.1016/S0168-3659(99)00139-X]
91. Park H, Park K, Kim D. Preparation and swelling behavior of chitosan-based superporous hydrogels for gastric retention application. J Biomed Mater Res A 2006; 76: 144-150 [PMID: 16258961 DOI: 10.1002/jbm.a.30533]
92. Zhang JX, Wang K, Mao ZF, Fan X, Jiang DL, Chen M, Cui L, Sun K, Dang SC. Application of liposomes in drug development-focus on gastroenterological targets. Int J Nanomedicine 2013; 8: 1325-1334 [PMID: 23630417 DOI: 10.2147/IJN. S42153]
93. Freund O. Biodistribution and gastrointestinal drug delivery of new lipidic multilamellar vesicles. Drug Deliv 2001; 8: 239-244 [PMID: 11757782 DOI: 10.1080/107175401317245921]
94. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005; 4: 145-160 [PMID: 15688077 DOI: 10.1038/nrd1632]
95. Gregoriadis G, Florence AT. Liposomes in drug delivery. Clinical, diagnostic and ophthalmic potential. Drugs 1993; 45: 15-28 [PMID: 7680982 DOI: 10.2165/00003495-199345010-00003]
96. Singh DY, Prasad NK. Double liposomes mediated dual drug targeting for treatment of Helicobacter pylori infections. Pharmazie 2011; 66: 368-373 [PMID: 21699071]
97. Jain P, Jain S, Prasad KN, Jain SK, Vyas SP. Polyelectrolyte coated multilayered liposomes (nanocapsules) for the treatment of Helicobacter pylori infection. Mol Pharm 2009; 6: 593-603 [PMID: 19718807 DOI: 10.1021/mp8002539]
98. Lin YH, Tsai SC, Lai CH, Lee CH, He ZS, Tseng GC. Genipin-cross-linked fucose-chitosan/heparin nanoparticles for the eradication of Helicobacter pylori. Biomaterials 2013; 34: 4466-4479 [PMID: 23499480 DOI: 10.1016/j.biomaterials.2013.02.028]
99. Ramteke S, Ganesh N, Bhattacharya S, Jain NK. Amoxicillin, clarithromycin, and omeprazole based targeted nanoparticles for the treatment of H. Pylori. J Drug Target 2009; 17: 225-234 [PMID: 19241256 DOI: 10.1080/10611860902718649]
100. Cao MB, Dong L, Chang XM, Zou BC, Qin B. Effect of Mexican tea herb and pilular adina herb on concrescence of gastric mucosa in experimental gastric ulcer rats. Chin J Integr Med 2007; 13: 132-136 [PMID: 17609913 DOI: 10.1007/s11655-007-0132-7]
101. Narayan S, Veeraraghavan M, Devi CS. Pterocarpus santalinus: an In Vitro study on its anti-Helicobacter pylori effect. Phytother Res 2007; 21: 190-193 [PMID: 17128431 DOI: 10.1002/ptr.2047]
102. Wang YC, Huang TL. Screening of anti-Helicobacter pylori herbs deriving from Taiwanese folk medicinal plants. FEMS Immunol Med Microbiol 2005; 43: 295-300 [PMID: 15681161 DOI: 10.1016/j.femsim.2004.09.008]